Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4

Evolent Health Inc Class A -6.76%

Evolent Health Inc Class A

EVH

3.17

-6.76%

Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE: EVH) with a Buy and lowers the price target from $6 to $4.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via